このエントリーをはてなブックマークに追加
ID 54603
JaLCDOI
フルテキストURL
Thumnail 70_5_409.pdf 1.89 MB
著者
Maeda, Yoshinobu Department of Hematology and Oncology, Okayama University Hospital
Nishimori, Hisakazu Department of Hematology and Oncology, Okayama University Hospital
Inamoto, Yoshihiro Department of Hematopoietic Stem Cell Transplantation, National Cancer Center Hospital
Nakamae, Hirohisa Department of Hematology, Osaka City University Hospital
Sawa, Masashi Department of Hematology and Oncology, Anjo Kosei Hospital
Mori, Yasuo Department of Medicine and Biosystemic Science, Kyushu University Graduate School of Medical Sciences
Ohashi, Kazuteru Hematology Division, Tokyo Metropolitan Cancer and Infectious Diseases Center
Fujiwara, Shin-ichiro Division of Hematology, Department of Medicine, Jichi Medical University
Tanimoto, Mitsune Department of Hematology and Oncology, Okayama University Hospital
抄録
Chronic graft-versus-host disease (GVHD) is a major cause of late death and morbidity following allogeneic hematopoietic cell transplantation (HSCT). Retinoic acid (tamibarotene) exerts multiple effects on cell differentiation and is clinically used for the treatment of acute promyelocytic leukemia. Tamibarotene down-regulates both Th1 and Th17 differentiation in donor T cells after allogeneic HSCT, resulting in attenuation of experimental chronic GVHD. Based on preclinical data, we have launched a phase II study of tamibarotene in patients with steroid-refractory chronic GVHD. This study will clarify whether tamibarotene can exert beneficial effects in patients with steroid-refractory chronic GVHD.
キーワード
Am80
tamibarotene
retinoid
chronic GVHD
steroid-refractory GVHD
Amo Type
Clinical Study Protocols
発行日
2016-10
出版物タイトル
Acta Medica Okayama
70巻
5号
出版者
Okayama University Medical School
開始ページ
409
終了ページ
412
ISSN
0386-300X
NCID
AA00508441
資料タイプ
学術雑誌論文
言語
English
著作権者
CopyrightⒸ 2016 by Okayama University Medical School
論文のバージョン
publisher
査読
有り
PubMed ID
Web of Sience KeyUT